DiaMedica Initiates Pivotal Trial Of DM199 For Treatment Of Acute Ischemic Stroke
Published
Sep 13 2021 at 1:09 PM GMT
Key
Points
Points
- (DMAC) announced the initiation of the first site for its pivotal ReMEDy2 Trial, a Phase 2/3 clinical study of DM199 for the treatment of acute ischemic stroke or AIS.
- The ReMEDy2 trial will assess the potential of DM199 to both improve recovery after a stroke and prevent stroke recurrence.
Trending
Stats
- Published Sep 13, 2021 1:09 PM GMT